American Marconi Wireless News - CBD Life Sciences Inc. (CBDL) Releases New CBD Suppositories for Vaginal & Rectal Relief

SCOTTSDALE, AZ / ACCESS Newswire / June 3, 2025 / CBD Life Sciences Inc. (OTC Pink:CBDL), a leader in the CBD wellness industry, proudly announces the launch of its groundbreaking line of CBD-infused vaginal and rectal suppositories. This innovative product is poised to transform the landscape of women's health by offering targeted relief for a myriad of conditions, including menstrual cramps, endometriosis, pelvic floor dysfunction, and gastrointestinal discomfort.

A Breakthrough for Localized, Fast-Acting Relief

Unlike oral CBD products, which must pass through the digestive system and may lose potency in the process, suppositories offer rapid absorption and superior bioavailability by delivering CBD directly into the bloodstream through the pelvic region or lower bowel.

This method allows patients to experience faster, more concentrated relief, particularly for conditions like:

• Endometriosis and menstrual pain

• Pelvic floor dysfunction

• Prostatitis and hemorrhoids

• Gastrointestinal disorders (IBS, IBD, Crohn's)

• Chronic pelvic pain syndrome

• Post-surgical recovery inflammation

By formulating this unique delivery system, CBD Life Sciences Inc. is opening the door to a broader application of CBD - bridging gaps in women's health, men's health, and gastrointestinal therapy.

The Science Behind the Relief

Recent studies show that CBD's anti-inflammatory, analgesic, and antispasmodic properties make it uniquely suited for conditions involving chronic pelvic or intestinal tension. In rectal use, CBD interacts with local CB1 and CB2 receptors in the digestive tract to reduce inflammation and modulate pain responses. For vaginal use, CBD has shown promise in reducing pelvic muscle tightness, cramping, and discomfort associated with reproductive or bladder-related disorders.

Market Potential: A Billion-Dollar Opportunity

The global pharmaceutical suppositories market was valued at approximately $1.6 billion in 2022 and is projected to reach $2.8 billion by 2032, growing at a compound annual growth rate (CAGR) of 5.7% . North America holds the largest market share, accounting for nearly two-fifths of the global revenue.

CBD Life Sciences Inc.'s entry into this burgeoning market positions the company at the forefront of a healthcare revolution, offering investors a unique opportunity to capitalize on the intersection of natural wellness and women's health.

Local Medical Community Endorsement

Several healthcare professionals in Scottsdale, Arizona, have approached CBD Life Sciences Inc., expressing keen interest in the therapeutic potential of these suppositories for their patients. This local engagement underscores the product's relevance and anticipated impact in the medical community, further validating its market readiness and clinical significance.

About CBD Life Sciences Inc. (CBDL)
CBD Life Sciences Inc. is a vertically integrated health and wellness company focused on cannabinoid innovation. With a robust pipeline of CBD, Delta-8, and other hemp-derived formulations, CBDL operates across direct-to-consumer, retail, and wholesale channels - including recent distribution on Walmart Marketplace and additional platforms coming soon.

Follow our social media for the latest updates!
X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: [email protected]

Stay Connected & Be the First to Try Our New Functional Mushroom Products!

Mushroom Madness Instagram: https://www.instagram.com/mushroom.madnessaz
Mushroom Madness Website: https://www.mushroommadness.shop

Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.

Contact Information
Lisa Nelson
CEO
[email protected]
4802091720

SOURCE: CBD Life Sciences Inc.

View the original press release on ACCESS Newswire

C.Garcia--AMWN